BI 1821736

· Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BI 1821736, covering 2025-07-08 to 2025-07-08. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer [Phase 1]